May 04, 2024 21:59 (IST)
Migraine treatment injection from Dr Reddy's Lab now available in the US
Hyderabad/Princeton-NJ, Apr 19 (IBNS) Promius Pharma LLC, a subsidiary of Dr. Reddy's Laboratories Ltd, has informed on Tuesday that its ZEMBRACE SymTouch (sumatriptan injection) 3 mg, which was approved by the FDA in January 2016 for the acute treatment of migraine with or without aura in adults, is now commercially available in the U.S.
The company said that ZEMBRACE SymTouch is a pre filled, low-dose, ready-to-use, 2-step autoinjector containing 3 mg of sumatriptan, a selective 5-HT1B/ID receptor agonist. Because ZEMBRACE SymTouch is a subcutaneous injection, it may lead to rapid relief of migraine.
Migraineurs often have more than one kind of attack. Different types of medications can be used to treat different types of attacks.
According to Roger Cady, MD, Associate Executive Chairman of the National Headache Foundation “ZEMBRACE SymTouch is a welcome addition to the toolkit for acute treatment of migraine. This 3-mg, easy to-use subcutaneous injection of sumatriptan may be desired by many migraine patients who need a medication that can rapidly treat migraine attacks. Also, the 3-mg dose allows for up to 4 doses of ZEMBRACE SymTouch in a 24-hour period, thus allowing dosing flexibility for patients.”
ZEMBRACE SymTouch is available as a box of 4 autoinjectors.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
Latest Headlines
Apple CEO Tim Cook expresses happiness over company's double-digit progress in India Sat, May 04 2024
Market Update: IPO performance, economic trends, and global Insights Sat, May 04 2024
6 Adani Group companies get show-cause notices from SEBI Sat, May 04 2024
RBI permits SPDs to borrow in foreign currency Sat, May 04 2024
Delhi High Court orders SpiceJet to pay $1.58 million to engine lessors by May 22: Report Fri, May 03 2024
Mahindra & Mahindra gets 674 patents in FY24 Fri, May 03 2024
JSW Infrastructure Q4FY24 PAT grows 9% YoY to Rs 329 cr Fri, May 03 2024
Mining sector registers record production in FY 2023-24 Fri, May 03 2024